Announces Results of Annual and Special
Meeting of Shareholders
TORONTO and HOUSTON, TX, Sept. 21,
2017 /CNW/ - Medicenna Therapeutics Corp.
("Medicenna" or the "Company") (TSX: MDNA), a
clinical stage immuno-oncology company, today announced that it has
appointed Dr. William Li to its
Board of Directors.
"We are delighted to appoint such an outstanding and experienced
oncology drug development expert to our Board of Directors" said
Dr. Fahar Merchant, Chairman,
President and CEO, "Dr. W. Li adds
depth to our existing Board as we position ourselves for clinical
success in 2018."
Dr. William Li is a seasoned
executive, leading innovation in cancer therapeutics, diagnostics,
and imaging for over two decades. He is CEO, President and
Co-Founder of the Angiogenesis Foundation and has served as
executive strategic consultant in oncology drug development for
Bayer, Genentech, Sanofi-Aventis, Novartis, Pfizer, among others,
and advised leaders at major investment banks. As an eminent
oncology innovator, Dr. Li has collaborated with major medical
academic centers, biopharmaceutical companies and government
agencies, including the NIH, NCI and the FDA. Dr. Li has extensive
expertise in tumor angiogenesis, in vivo angiogenesis
models, angiogenesis therapeutic development and clinical trials.
He is a published author in leading research journals, peer
reviewed publications and has been a speaker at TED. A graduate of
Harvard College and the University of
Pittsburgh School of Medicine, Dr. Li completed his
residency training at the Massachusetts
General Hospital. Dr. Li has held appointments on the clinical
faculties of Harvard Medical School, Tufts
University, and at Dartmouth Medical School. He is currently
a member of the board of directors of another immuno-oncology
company, Leap Therapeutics, Inc (LPTX, Nasdaq).
AGM Results:
Medicenna held its annual and special meeting of shareholders
today, September 21, 2017 in
Toronto (the "Meeting"). A total of 75.83% of the issued and
outstanding common shares of the Company were represented in person
and by proxy at the Meeting.
Medicenna is pleased to announce that all of the nominees listed
in the management proxy circular dated August 15,
2017 were elected as directors. Each of the directors
was elected with greater than 99% of the votes cast by shareholders
present at the Meeting or represented by proxy. The results of the
vote are detailed below:
Nominee
|
Votes
For
|
% of Votes
For
|
Votes
Withheld
|
% of Votes
Withheld
|
Dr. Fahar
Merchant
|
18,445,853
|
99.92
|
14,000
|
0.08
|
Mr. Albert
Beraldo
|
18,445,853
|
99.92
|
14,000
|
0.08
|
Dr. William
Li
|
18,445,853
|
99.92
|
14,000
|
0.08
|
Ms. Rosemina
Merchant
|
18,454,853
|
99.97
|
5,000
|
0.03
|
Dr. Chandrakant
Panchal
|
18,445,853
|
99.92
|
14,000
|
0.08
|
Mr. Andrew
Strong
|
18,445,853
|
99.92
|
14,000
|
0.08
|
Medicenna shareholders also voted to re-appoint Davidson
& Company LLP as auditor of the Company.
In addition, all other resolutions placed before the Meeting
were approved by the shareholders, including (i) a resolution
for the approval of the 2017 stock option plan of the Company and
(ii) a resolution for the approval of the continuance of the
Company under the laws of Canada.
About Medicenna Therapeutics Corp.
Medicenna is a clinical stage immuno-oncology company developing
novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™
and first in class Empowered Cytokines™ (ECs). Its wholly
owned subsidiary, Houston-based
Medicenna BioPharma, is specifically targeting the Interleukin-4
Receptor (IL4R), which is over-expressed by at least 20 different
types of cancer affecting more than one million new cancer patients
every year. Medicenna's lead IL4-EC, MDNA55 is enrolling patients
in a Phase 2b clinical trial for rGBM at leading brain cancer
centres in the US. MDNA55 has completed 3 clinical trials in 72
patients, including 66 adults with rGBM, demonstrated compelling
efficacy and obtained Fast-Track and Orphan Drug status from USFDA.
Unlike most other cancer therapies, Medicenna's IL4-ECs have the
potential to purge both the tumor and the immunosuppressive tumor
microenvironment, offering a unique treatment paradigm for a large
majority of cancer patients.
For more information, please visit www.medicenna.com.
This news release contains forward-looking statements
relating to the future operations of the Company and other
statements that are not historical facts. Forward-looking
statements are often identified by terms such as "will", "may",
"should", "anticipate", "expects" and similar expressions. All
statements other than statements of historical fact, included in
this release, including, without limitation, statements regarding
future plans and objectives of the Company, the possibility of
clinical success in 2018 and others are forward-looking statements
that involve risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and actual results
and future events could differ materially from those anticipated in
such statements. Important factors that could cause actual results
to differ materially from the Company's expectations include the
risks detailed in the annual information form of the Company dated
June 15, 2017 and in other filings
made by the Company with the applicable securities regulators from
time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements only
as expressly required by Canadian securities law.
SOURCE Medicenna Therapeutics Corp.